Market Overview

AEON, Authentidate Launch Cancer Genetic Testing With Telehealth-Based Genetic Counseling

Share:

Authentidate Holding Corp. (Nasdaq: ADAT), has partnered with AEON Clinical Laboratories to nationally launch Cancer Detect Profile®, a 38-gene cancer genetic test coupled with telehealth-based genetic counseling for the prescribing physicians. The test is designed to identify patients with increased risk of colorectal, breast, pancreatic, ovarian, gastric, melanoma, stomach and other cancers. The test is now available for use by AEON's base of more than 6,000 physicians who annually treat more than one million patients nationwide.

The Centers for Medicare and Medicaid Services ("CMS") sets the guidelines for billing rates and depending on the number of cancers tested, billable amounts are expected to range between $3,000 and $6,000 per patient. In 2014, there were an estimated 1.6 million new cancer cases diagnosed and 585,720 cancer deaths in the U.S. Early testing and detection are critical to successful treatment outcomes.

"This pioneering offering enhances our group of leading Cancer Genomics tests and uniquely integrates our board-certified genetic counselors remotely, via Authentidate's telehealth platform," said Richard Hersperger, CEO of AEON. "Cancer Detect Profile is a significant innovation in personalized medicine and exemplifies our commitment to delivering a comprehensive offering of state of

See full press release

Posted-In: News FDA Press Releases

 

Related Articles (ADAT)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

WebMD Is Quickly Becoming A Wall Street Favorite

JP Morgan Desk Comments: Remain Underweight ORCL, Believes Investors Will Struggle To Explain The Company's Reduction